Advances in mRNA non-viral delivery approaches

[Display omitted] Messenger RNAs (mRNAs) present a great potential as therapeutics for the treatment and prevention of a wide range of human pathologies, allowing for protein replacement, vaccination, cancer immunotherapy, and genomic engineering. Despite advances in the design of mRNA-based therape...

Full description

Saved in:
Bibliographic Details
Published inAdvanced drug delivery reviews Vol. 177; p. 113930
Main Authors Ibba, Maria L., Ciccone, Giuseppe, Esposito, Carla L., Catuogno, Silvia, Giangrande, Paloma H.
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.10.2021
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:[Display omitted] Messenger RNAs (mRNAs) present a great potential as therapeutics for the treatment and prevention of a wide range of human pathologies, allowing for protein replacement, vaccination, cancer immunotherapy, and genomic engineering. Despite advances in the design of mRNA-based therapeutics, a key aspect for their widespread translation to clinic is the development of safe and effective delivery strategies. To this end, non-viral delivery systems including peptide-based complexes, lipidic or polymeric nanoparticles, and hybrid formulations are attracting growing interest. Despite displaying somewhat reduced efficacy compared to viral-based systems, non-viral carriers offer important advantages in terms of biosafety and versatility. In this review, we provide an overview of current mRNA therapeutic applications and discuss key biological barriers to delivery and recent advances in the development of non-viral systems. Challenges and future applications of this novel therapeutic modality are also discussed.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0169-409X
1872-8294
DOI:10.1016/j.addr.2021.113930